4.2 SSRIs, SNRIs, Novel Antidepressants, and Serotonin Syndrome

Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) represent the primary pharmacological foundation for modern depressive and anxiety disorders. Although their safety margin in overdose is substantially wider than that of first-generation tricyclic antidepressants, distinct agents within these classes exhibit life-threatening cardiotoxicity, delayed neurotoxicity, and intractable seizures. Furthermore, the convergence of multiple serotonergic pharmacotherapies precipitates Serotonin Syndrome (serotonin toxicity)—an acute, hyperthermic, neuromuscular crisis requiring rapid recognition and specialized clinical toxicology management.

---

Class Toxicology: SSRIs, SNRIs, and Novel Agents

1. Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs—including fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram, and escitalopram—selectively inhibit the presynaptic serotonin reuptake transporter (SERT). In isolated overdose, fluoxetine, sertraline, and paroxetine typically produce mild, self-limited clinical effects, such as nausea, vomiting, dizziness, mild sinus tachycardia, and fine tremor.

However, citalopram (a racemic mixture of R- and S-enantiomers) and escitalopram (the pure S-enantiomer) exhibit unique and dangerous cardiotoxicity:

• Mechanism of Cardiotoxicity: Citalopram and escitalopram, along with their active metabolite didemethylcitalopram (DDCT), exert potent, concentration-dependent blockade of the rapid delayed rectifier potassium current (IKr) encoded by the human ether-à-go-go-related gene (HERG). Blockade of IKr impairs ventricular Phase 3 repolarization, manifesting as prolongation of the corrected QT (QTc) interval.
• Clinical Thresholds: Ingestions of citalopram exceeding 600 mg or escitalopram exceeding 300 mg carry a high risk of marked QTc prolongation (>500 ms) and malignant ventricular dysrhythmias, specifically Torsades de Pointes (TdP). Generalized seizures also occur in up to 15% of significant ingestions.
• Monitoring Window: Continuous cardiac telemetry is mandatory for a minimum of 8 to 12 hours post-ingestion. If the QTc interval is prolonged, monitoring must continue until the interval normalizes below 460 ms in men or 470 ms in women.

2. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

SNRIs—principally venlafaxine, desvenlafaxine, and duloxetine—inhibit both SERT and the norepinephrine transporter (NET). Among all modern non-tricyclic antidepressants, venlafaxine is responsible for the highest rate of intensive care unit admissions and fatalities in overdose:

• Convulsant Potential: Venlafaxine overdoses provoke seizures in approximately 10% to 14% of cases, often occurring at doses as low as 1.5 to 2.25 grams. Seizures are frequently recurrent, may occur without prodromal warning signs, and carry a risk of status epilepticus.
• Myocardial Conduction Delay: At elevated concentrations, venlafaxine exerts quinidine-like fast sodium channel blockade (Phase 0 inhibition) alongside potassium channel blockade. Patients present with sinus tachycardia, QRS widening (>100 ms), bundle branch blocks, and QTc prolongation.
• Stress-Induced Cardiomyopathy: Massive venlafaxine overdoses can cause profound catecholamine-mediated myocardial stunning (Takotsubo cardiomyopathy) resulting in acute cardiogenic shock and pulmonary edema.
• Treatment Pearls: QRS widening from venlafaxine responds to hypertonic sodium bicarbonate boluses (1–2 mEq/kg IV), mirroring cyclic antidepressant management protocols.

3. Bupropion: High-Yield Overdose Profile

Bupropion is a monocyclic aminoketone structurally related to diethylpropion and synthetic cathinones ("bath salts"). It acts as a selective norepinephrine-dopamine reuptake inhibitor (NDRI) without direct serotonergic activity:

• Seizure Predisposition: Bupropion carries the highest incidence of drug-induced seizures among all modern psychotropics. In acute overdose, generalized tonic-clonic seizures occur in 10% to 35% of patients.
• Delayed Toxicity Window: Because most prescribed formulations are modified-release (Sustained-Release [SR] or Extended-Release [XL]), gastrointestinal absorption is prolonged and erratic. Seizure onset is characteristically delayed, frequently occurring 12 to 24 hours post-ingestion, even in patients who were completely asymptomatic during early emergency department observation.
• Cardiovascular Collapse: Beyond seizures, massive bupropion overdose impairs myocardial gap-junction intercellular communication and blocks cardiac sodium and potassium channels. This causes intraventricular conduction delay (wide QRS), QTc prolongation, severe sinus tachycardia, and refractory cardiogenic shock unresponsive to standard inotropic support.
• Triage and Observation Mandate: Any intentional overdose of modified-release bupropion requires mandatory admission for continuous cardiac telemetry and seizure precautions for a minimum of 24 hours.

---

Serotonin Syndrome (Serotonin Toxicity)

Pathophysiology and Precipitants

Serotonin Syndrome is a predictable, concentration-dependent toxic state resulting from excessive intrasynaptic stimulation of serotonin receptors, predominantly the 5-HT2A receptor subtype within the brainstem and spinal cord, with modulatory contributions from 5-HT1A receptors. It is not an idiosyncratic reaction; it occurs following therapeutic dose escalation, acute overdose, or most commonly, the concurrent administration of two or more agents that enhance serotonergic neurotransmission through synergistic mechanisms:

1. Inhibition of Serotonin Breakdown (MAO Inhibition): Phenelzine, tranylcypromine, selegiline, moclobemide, linezolid (oxazolidinone antibiotic with reversible MAO-A inhibition), and intravenous methylene blue (potent MAO-A inhibitor).
2. Inhibition of Serotonin Reuptake: SSRIs, SNRIs, TCAs (especially clomipramine and imipramine), tramadol, meperidine, methadone, and dextromethorphan.
3. Increased Serotonin Synthesis or Release: L-tryptophan, amphetamines, MDMA (3,4-methylenedioxymethamphetamine / "ecstasy"), synthetic cathinones, and cocaine.
4. Direct Serotonin Receptor Agonism: Triptans (sumatriptan), buspirone, and ergot alkaloids.

The most severe and rapidly fatal cases almost universally involve the combination of a Monoamine Oxidase Inhibitor (MAOI) with an SSRI, SNRI, or serotonergic opioid (such as tramadol, meperidine, or dextromethorphan).

Diagnostic Criteria: The Hunter Criteria

The Hunter Serotonin Toxicity Criteria represents the internationally accepted, validated diagnostic gold standard. It demonstrates superior sensitivity (84%) and specificity (97%) compared to the historical Sternbach criteria. To fulfill the Hunter Criteria, a patient must have been exposed to a serotonergic agent (remember that fluoxetine and its active metabolite persist for weeks after the last dose) AND exhibit at least one of the following five diagnostic rules:

1. Spontaneous clonus (continuous, rhythmic involuntary muscular contractions).
2. Inducible clonus AND (agitation OR diaphoresis).
3. Ocular clonus (slow, continuous, bilateral horizontal roving eye movements) AND (agitation OR diaphoresis).
4. Tremor AND hyperreflexia.
5. Hypertonia AND core body temperature > 38.0°C (100.4°F) AND (ocular clonus OR inducible clonus).

CSPI Clinical Pearl — The Primacy of Clonus: Clonus (spontaneous, inducible, or ocular) is the single most important and specific clinical sign of serotonin toxicity. Tendon reflexes and clonus are characteristically symmetric and markedly more pronounced in the lower extremities than in the upper extremities.

---

Differential Diagnosis: Hyperthermic Toxidromes Matrix

Differentiating Serotonin Syndrome from Neuroleptic Malignant Syndrome (NMS) and Anticholinergic Toxicity is an essential competency for poison information specialists. While all three share autonomic instability, altered mental status, and hyperthermia, their physical examination findings are distinct.

---

Stepwise Clinical Management

1. Immediate Cessation of Serotonergic Pharmacotherapy

All potential serotonergic agents must be discontinued immediately. In mild cases, drug cessation and supportive care alone result in complete symptom resolution within 24 to 36 hours.

2. Neuromuscular and Autonomic Control: Intravenous Benzodiazepines

Intravenous benzodiazepines (lorazepam 2 to 4 mg IV, or diazepam 5 to 10 mg IV, titrated every 5 to 10 minutes) are the cornerstone of medical therapy. Benzodiazepines enhance central GABAergic inhibition, blunting excessive sympathetic outflow, calming agitated motor behavior, reducing muscular thermogenesis, and preventing rhabdomyolysis and secondary renal failure. Physical restraints are strictly contraindicated because isometric muscle contractions against restraints dramatically accelerate hyperthermia and metabolic acidosis.

3. Aggressive Hyperthermia Management

Elevated core temperature in Serotonin Syndrome is generated purely by excessive muscular contraction and rigidity, not by an alteration in the hypothalamic temperature set-point:

• Antipyretics are Ineffective and Contraindicated: Acetaminophen, aspirin, and NSAIDs must not be administered; they provide zero therapeutic efficacy and increase the risk of hepatic and renal injury.
• External Active Cooling: Evaporative cooling (undressing the patient, applying misted lukewarm water, and directing high-velocity fans across the skin) alongside ice packs to the axillae, groin, and neck must be instituted immediately.
• Critical Hyperthermia (>41.1°C / 106°F): If core temperature exceeds 41.1°C or if severe muscle rigidity impairs respiratory excursion, the patient requires emergent endotracheal intubation, mechanical ventilation, and immediate neuromuscular paralysis with a non-depolarizing paralytic agent (e.g., vecuronium or rocuronium). Complete chemical paralysis abolishes muscle contraction, rapidly arresting fatal thermogenesis.
• Succinylcholine is Strictly Contraindicated: Depolarizing neuromuscular blockade with succinylcholine in the setting of severe hyperthermia, muscle breakdown, and rigidity can precipitate massive rhabdomyolysis, hyperkalemia, and cardiac arrest.

4. Specific 5-HT2A Receptor Antagonist: Cyproheptadine

For moderate-to-severe serotonin toxicity refractory to benzodiazepines and cooling measures, cyproheptadine is the antidote of choice. Cyproheptadine is a potent, non-selective antagonist at 5-HT2A and 5-HT1A receptors, while possessing mild anticholinergic and H1-antihistaminic activity:

• Initial Loading Dose: Administer 12 mg orally (or crushed and dissolved via a nasogastric or orogastric tube in intubated patients).
• Repeat Titration: If symptoms persist or worsen after 2 hours, administer an additional 2 mg every 2 hours until clinical improvement is documented.
• Maintenance Regimen: Once control is achieved, transition to a maintenance dose of 4 to 8 mg orally every 6 hours for 24 to 48 hours to prevent recrudescence of toxicity as the offending serotonergic drug clears.
• Maximum Adult Dose: Total daily dose should not exceed 32 mg in adults (or 0.25 mg/kg/day in children).
• Formulation Consideration: Cyproheptadine is available only as an oral tablet or liquid suspension; no parenteral (IV) formulation exists.

Other Non-Cyclic Antidepressants: MAOIs, Trazodone, Nefazodone, and Mirtazapine

The official topic list names monoamine oxidase inhibitors, trazodone and nefazodone, duloxetine, and venlafaxine alongside the SSRIs. These agents behave differently in overdose from the SSRIs covered above.

Monoamine Oxidase Inhibitors (MAOIs)

Phenelzine, tranylcypromine, isocarboxazid, and selegiline (including the transdermal patch) block the enzyme that degrades norepinephrine, serotonin, and dopamine. Three distinct emergencies occur.

The interaction window outlasts the drug: irreversible MAOIs require new enzyme synthesis, so about 2 weeks should pass after stopping an MAOI before another serotonergic drug is started, and about 5 weeks after fluoxetine before an MAOI is started.

Trazodone, Nefazodone, Mirtazapine, and Duloxetine

Triage pearl: an asymptomatic patient early after an MAOI overdose is not safe to discharge. Toxicity can be delayed for many hours, so every intentional or large MAOI ingestion is referred and monitored for at least 24 hours.